Free Trial

LENZ Therapeutics (LENZ) Financials

LENZ Therapeutics logo
$29.53 +0.82 (+2.86%)
Closing price 04:00 PM Eastern
Extended Trading
$29.56 +0.02 (+0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for LENZ Therapeutics

Annual Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-50 -70 -101
Consolidated Net Income / (Loss)
-50 -70 -101
Net Income / (Loss) Continuing Operations
-50 -70 -101
Total Pre-Tax Income
-50 -70 -101
Total Operating Income
-59 -72 -106
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
59 72 106
Selling, General & Admin Expense
29 13 33
Research & Development Expense
30 60 73
Total Other Income / (Expense), net
8.84 2.28 4.59
Interest & Investment Income
8.55 2.19 -
Other Income / (Expense), net
0.29 0.09 4.59
Income Tax Expense
0.00 -0.18 -
Basic Earnings per Share
($2.34) ($35.71) ($1.84)
Weighted Average Basic Shares Outstanding
21.28M 1.96M 54.87M
Diluted Earnings per Share
($2.34) ($35.71) ($1.84)
Weighted Average Diluted Shares Outstanding
21.28M 1.96M 54.87M
Weighted Average Basic & Diluted Shares Outstanding
27.54M 58.24M 58.16M

Quarterly Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-15 -13 -10 -10 -17 -24 -19 -15 -13 -25 -25
Consolidated Net Income / (Loss)
-15 -13 -10 -10 -17 -24 -19 -15 -13 -25 -25
Net Income / (Loss) Continuing Operations
-15 -13 -10 -10 -17 -24 -19 -15 -13 -24 -25
Total Pre-Tax Income
-15 -13 -10 -10 -17 -24 -19 -15 -13 -24 -25
Total Operating Income
-17 -15 -13 -14 -16 -25 -20 -15 -13 -27 -26
Total Gross Profit
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses
17 15 13 14 16 25 20 15 13 27 26
Selling, General & Admin Expense
11 9.36 6.49 7.41 5.55 5.45 2.86 2.32 2.29 8.29 7.85
Research & Development Expense
5.82 5.87 6.45 6.95 11 20 17 13 10 18 18
Total Other Income / (Expense), net
2.31 2.57 2.73 4.10 -0.56 1.12 0.99 0.23 -0.05 2.28 1.47
Interest & Investment Income
2.32 2.57 2.74 2.46 0.79 0.85 1.09 0.25 0.00 - -
Other Income / (Expense), net
-0.01 0.01 -0.01 1.64 -1.35 0.27 -0.10 -0.02 -0.05 2.28 1.47
Basic Earnings per Share
($0.53) $1.97 ($0.38) ($0.40) ($3.53) ($12.06) ($9.62) ($7.53) ($6.50) ($0.43) ($0.45)
Weighted Average Basic Shares Outstanding
27.53M 21.28M 27.17M 25.61M 4.72M 1.96M 1.96M 1.96M 1.95M 54.87M 55.21M
Diluted Earnings per Share
($0.53) $1.97 ($0.38) ($0.40) ($3.53) ($12.06) ($9.62) ($7.53) ($6.50) ($0.43) ($0.45)
Weighted Average Diluted Shares Outstanding
27.53M 21.28M 27.17M 25.61M 4.72M 1.96M 1.96M 1.96M 1.95M 54.87M 55.21M
Weighted Average Basic & Diluted Shares Outstanding
28.15M 27.54M 27.50M 27.50M 25.53M 58.24M 58.00M 57.98M 58.10M 58.16M 58.15M

Annual Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-15 -9.30 -329
Net Cash From Operating Activities
-59 -60 -88
Net Cash From Continuing Operating Activities
-59 -60 -88
Net Income / (Loss) Continuing Operations
-50 -70 -101
Consolidated Net Income / (Loss)
-50 -70 -101
Depreciation Expense
0.06 0.02 2.35
Amortization Expense
-4.02 -1.06 -1.60
Non-Cash Adjustments To Reconcile Net Income
7.43 1.41 20
Changes in Operating Assets and Liabilities, net
-13 9.41 -7.30
Net Cash From Investing Activities
-154 -30 -242
Net Cash From Continuing Investing Activities
-154 -30 -242
Purchase of Property, Plant & Equipment
-0.47 -0.03 -6.59
Purchase of Investments
-242 -52 -406
Sale and/or Maturity of Investments
88 23 170
Net Cash From Financing Activities
199 81 0.60
Net Cash From Continuing Financing Activities
199 81 0.60
Repurchase of Common Equity
0.00 -2.48 -0.08
Issuance of Preferred Equity
0.00 83 -
Issuance of Common Equity
80 0.00 0.66
Other Financing Activities, net
119 0.20 0.02

Quarterly Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
2.88 -21 -43 -116 165 -7.71 -32 -40 70 -8.66 -19
Net Cash From Operating Activities
-16 -9.08 -11 -16 -24 -21 -13 -14 -13 -22 -22
Net Cash From Continuing Operating Activities
-16 -9.08 -11 -16 -24 -21 -13 -14 -13 -22 -22
Net Income / (Loss) Continuing Operations
-15 -13 -10 -10 -17 -24 -19 -15 -13 -25 -25
Consolidated Net Income / (Loss)
-15 -13 -10 -10 -17 -24 -19 -15 -13 -25 -25
Depreciation Expense
0.04 0.03 0.01 0.02 0.01 0.00 0.00 0.00 0.00 0.68 0.65
Amortization Expense
-1.13 -1.42 -1.36 -0.96 -0.28 -0.51 -0.53 -0.02 0.00 -1.12 -0.56
Non-Cash Adjustments To Reconcile Net Income
2.56 1.65 2.19 1.60 1.99 0.44 0.60 0.21 0.16 5.53 4.62
Changes in Operating Assets and Liabilities, net
-2.97 3.33 -1.21 -6.20 -9.01 2.98 5.72 1.00 -0.29 -2.92 -2.24
Net Cash From Investing Activities
19 -12 -62 -98 18 15 -18 -27 -0.01 14 3.50
Net Cash From Continuing Investing Activities
19 -12 -62 -98 18 15 -18 -27 -0.01 14 3.50
Purchase of Property, Plant & Equipment
-0.11 -0.15 -0.19 -0.13 0.00 - - -0.02 -0.01 -1.02 -0.92
Purchase of Investments
-33 -47 -84 - - -5.83 -19 - - -66 -86
Sale and/or Maturity of Investments
52 35 22 13 18 21 1.50 - 0.00 80 90
Net Cash From Financing Activities
0.04 0.05 30 -2.14 171 -1.91 -0.57 - 83 0.24 -0.06
Net Cash From Continuing Financing Activities
0.04 0.05 30 -2.14 171 -1.91 -0.57 - 83 0.24 -0.06
Issuance of Common Equity
0.00 -0.09 30 -3.56 53 - - - 0.00 0.24 -
Other Financing Activities, net
0.04 0.14 0.04 1.43 118 - - - 0.20 0.00 0.01

Annual Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
215 70 322
Total Current Assets
212 67 275
Cash & Equivalents
20 35 48
Restricted Cash
0.11 0.00 0.00
Short-Term Investments
189 31 220
Prepaid Expenses
2.77 1.45 7.14
Plant, Property, & Equipment, net
0.65 0.05 23
Total Noncurrent Assets
2.74 3.08 24
Other Noncurrent Operating Assets
2.74 3.08 8.59
Total Liabilities & Shareholders' Equity
215 70 322
Total Liabilities
11 20 26
Total Current Liabilities
10 19 13
Accounts Payable
4.26 5.71 2.61
Accrued Expenses
6.15 13 2.59
Total Noncurrent Liabilities
0.81 1.18 13
Other Noncurrent Operating Liabilities
0.81 1.18 13
Commitments & Contingencies
0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 143 0.00
Total Equity & Noncontrolling Interests
204 -93 296
Total Preferred & Common Equity
204 -93 296
Total Common Equity
204 -93 296
Common Stock
349 2.53 540
Retained Earnings
-145 -95 -242
Accumulated Other Comprehensive Income / (Loss)
0.20 0.01 -1.05

Quarterly Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
201 224 203 217 266 287 310 335
Total Current Assets
198 221 199 217 239 251 270 298
Cash & Equivalents
23 41 84 200 183 129 70 56
Restricted Cash
0.11 0.11 0.11 0.11 - - - -
Short-Term Investments
171 176 112 13 51 118 194 235
Prepaid Expenses
3.77 3.48 3.12 3.28 4.78 2.88 6.21 6.81
Plant, Property, & Equipment, net
0.93 0.37 0.16 0.05 13 18 33 13
Total Noncurrent Assets
2.47 2.93 3.13 0.60 15 18 6.62 23
Other Noncurrent Operating Assets
2.47 2.93 3.13 0.60 15 18 6.62 9.68
Total Liabilities & Shareholders' Equity
201 224 203 217 266 287 310 335
Total Liabilities
9.24 8.73 9.72 19 62 63 34 18
Total Current Liabilities
8.57 7.71 8.58 19 13 12 14 14
Accounts Payable
3.66 2.76 4.41 7.13 3.75 2.72 1.99 3.97
Accrued Expenses
4.91 4.95 4.18 12 3.45 4.37 7.91 1.65
Total Noncurrent Liabilities
0.67 1.02 1.14 0.27 50 51 19 4.87
Other Noncurrent Operating Liabilities
0.67 1.02 1.14 0.27 50 51 19 4.87
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
192 215 193 198 204 224 276 316
Total Preferred & Common Equity
192 215 193 198 204 224 276 316
Total Common Equity
192 215 193 198 204 224 276 316
Common Stock
352 347 315 310 548 546 543 536
Retained Earnings
-160 -132 -122 -112 -344 -322 -266 -218
Accumulated Other Comprehensive Income / (Loss)
0.12 0.52 -0.06 -0.00 -0.10 -0.27 -0.47 -1.60

Annual Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
0.00% 0.00% 0.00%
EBITDA Growth
15.12% 26.84% -43.23%
EBIT Growth
19.37% 28.42% -42.81%
NOPAT Growth
19.08% 31.44% -74.77%
Net Income Growth
28.87% 30.76% -42.81%
EPS Growth
93.45% -1,840.76% 24.90%
Operating Cash Flow Growth
1.64% 31.37% -66.46%
Free Cash Flow Firm Growth
-123.61% 71.31% -0.77%
Invested Capital Growth
66.53% -218.65% 80.10%
Revenue Q/Q Growth
0.00% 0.00% 0.00%
EBITDA Q/Q Growth
47.32% -0.43% -6.72%
EBIT Q/Q Growth
51.46% -0.34% -5.81%
NOPAT Q/Q Growth
55.31% 2.38% -7.98%
Net Income Q/Q Growth
56.51% 1.28% -33.54%
EPS Q/Q Growth
-113.64% -48.30% -132.74%
Operating Cash Flow Q/Q Growth
41.14% 2.36% -8.42%
Free Cash Flow Firm Q/Q Growth
57.37% -115.89% 0.00%
Invested Capital Q/Q Growth
-160.69% 49.59% 12.10%
Profitability Metrics
- - -
Gross Margin
0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 99.74% 100.00%
Interest Burden Percent
85.33% 96.97% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-39.07% -40.33% -29.71%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -803.61%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-17.08% -23.66% -29.71%
Return on Equity Simple (ROE_SIMPLE)
-24.39% 75.47% -34.11%
Net Operating Profit after Tax (NOPAT)
-41 -51 -74
NOPAT Margin
0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-6.36% -11.03% -8.21%
Return On Investment Capital (ROIC_SIMPLE)
-20.10% 54.69% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-58 -72 -101
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-62 -73 -100
Valuation Ratios
- - -
Price to Book Value (P/BV)
3.89 0.00 0.65
Price to Tangible Book Value (P/TBV)
3.89 0.00 0.65
Price to Revenue (P/Rev)
0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-1.08 -1.01 -0.97
Leverage Ratio
1.12 1.13 1.06
Compound Leverage Factor
0.96 1.10 1.06
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 282.94% 0.00%
Common Equity to Total Capital
100.00% -182.94% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
41.74 0.17 3.41
Noncontrolling Interest Sharing Ratio
56.28% 41.33% 0.00%
Liquidity Ratios
- - -
Current Ratio
20.36 3.63 21.11
Quick Ratio
20.09 3.55 20.57
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-51 -23 -80
Operating Cash Flow to CapEx
-12,690.38% -201,266.67% -1,334.24%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
-5.06 -15 13
Invested Capital Turnover
0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
10 -28 5.67
Enterprise Value (EV)
585 230 -90
Market Capitalization
794 152 193
Book Value per Share
$7.42 ($1.60) $5.10
Tangible Book Value per Share
$7.42 ($1.60) $5.10
Total Capital
204 51 296
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-209 -66 -284
Capital Expenditures (CapEx)
0.47 0.03 6.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-7.63 -17 -5.91
Debt-free Net Working Capital (DFNWC)
202 49 262
Net Working Capital (NWC)
202 49 262
Net Nonoperating Expense (NNE)
8.74 19 27
Net Nonoperating Obligations (NNO)
-209 -66 -284
Total Depreciation and Amortization (D&A)
-3.96 -1.04 0.75
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($2.34) ($2.19) ($1.84)
Adjusted Weighted Average Basic Shares Outstanding
21.28M 57.02M 54.87M
Adjusted Diluted Earnings per Share
($2.34) ($2.19) ($1.84)
Adjusted Weighted Average Diluted Shares Outstanding
21.28M 57.02M 54.87M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
27.54M 58.24M 58.16M
Normalized Net Operating Profit after Tax (NOPAT)
-41 -51 -74
Normalized NOPAT Margin
0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -3.54% -0.08%

Quarterly Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-1.89% 34.14% 30.21% 8.90% -39.78% -1.26% 16.68% 40.79% 50.27% -33.95% -70.85%
EBIT Growth
2.83% 38.45% 35.13% 15.09% -37.62% -1.01% 19.11% 42.25% 51.19% -29.30% -69.15%
NOPAT Growth
-5.24% 39.07% 34.84% 4.06% -27.52% 6.59% 24.05% 44.13% 51.40% -41.24% -79.11%
Net Income Growth
12.19% 46.60% 45.90% 30.37% -31.40% 3.69% 23.51% 43.22% 50.96% -3,257.77% -69.15%
EPS Growth
84.99% 116.34% 96.05% 94.69% 45.69% -2,704.65% -2,037.78% -1,468.75% -1,254.17% -106.12% -60.71%
Operating Cash Flow Growth
32.95% 56.71% 19.16% -16.79% -87.04% 6.51% 41.09% 38.79% 39.75% -43.84% -44.13%
Free Cash Flow Firm Growth
-255.34% -299.87% -235.20% -229.50% 236.73% 142.49% 212.05% 174.89% 56.98% 0.00% -59.05%
Invested Capital Growth
86.34% 66.53% 93.53% 86.31% -225.54% -218.65% -363.85% -337.29% 31.97% 80.10% 119.44%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-8.57% -16.20% -4.70% 22.86% 74.49% -23.14% -36.67% -18.35% 49.16% -1.31% 2.88%
EBIT Q/Q Growth
-11.34% -17.50% -1.84% 27.06% 76.60% -23.83% -33.31% -18.21% 48.24% 0.83% 4.84%
NOPAT Q/Q Growth
-11.21% -17.61% 9.80% 10.79% 80.52% -25.79% -32.80% -18.57% 52.84% -2.28% 2.32%
Net Income Q/Q Growth
-15.55% -23.86% 0.38% 38.41% 77.47% -25.49% -28.21% -16.23% 48.49% 0.34% 4.84%
EPS Q/Q Growth
-126.90% 618.42% 5.00% 88.67% -128.86% -25.36% -27.76% -15.85% -1,411.63% 4.44% 6.25%
Operating Cash Flow Q/Q Growth
-76.79% 14.20% 33.01% 34.01% 47.82% -60.22% 3.22% -5.67% 42.94% -0.95% -0.56%
Free Cash Flow Firm Q/Q Growth
-20.68% 44.18% -20.13% -291.94% 153.72% -62.24% 15.07% 302.66% 51.75% 0.42% 23.09%
Invested Capital Q/Q Growth
58.89% -160.69% 41.27% 78.29% -0.73% 49.59% -24.19% -299.10% -4.80% 12.10% 11.68%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.01% 100.00% 100.00% 100.00% 99.25% 100.00% 100.00% 100.00% 100.50% 100.00%
Interest Burden Percent
86.29% 83.14% 78.87% 80.63% 95.48% 96.55% 94.56% 98.32% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-24.47% -39.07% -54.59% -59.04% -53.79% -40.33% -27.23% -27.26% -27.57% -29.71% -21.12%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -633.70% -803.61% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-24.47% -17.08% -54.59% -59.04% -53.79% -23.66% -27.23% -27.26% -27.57% -29.71% -21.12%
Return on Equity Simple (ROE_SIMPLE)
-24.86% 0.00% -53.16% -63.81% -64.38% 0.00% -34.74% -34.21% -31.82% 0.00% -23.91%
Net Operating Profit after Tax (NOPAT)
-12 -11 -9.06 -10 -11 -17 -14 -10 -8.83 -19 -18
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-1.36% -1.45% -0.51% -0.09% -2.26% -3.55% -1.85% -1.48% -1.25% -1.78% -1.82%
Return On Investment Capital (ROIC_SIMPLE)
-6.17% -5.22% - - - 18.87% - - - - -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-17 -15 -13 -13 -17 -25 -20 -15 -13 -24 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-18 -17 -14 -14 -18 -25 -20 -15 -13 -25 -25
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.69 3.89 3.03 2.29 6.54 0.00 0.70 0.67 0.52 0.65 0.58
Price to Tangible Book Value (P/TBV)
3.69 3.89 3.03 2.29 6.54 0.00 0.70 0.67 0.52 0.65 0.58
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.04 -1.08 -1.08 -1.07 -1.01 -1.01 -1.04 -1.02 -0.97 -0.97 -0.98
Leverage Ratio
1.07 1.12 1.17 1.17 1.11 1.13 1.15 1.14 1.08 1.06 1.05
Compound Leverage Factor
0.93 0.93 0.92 0.95 1.06 1.09 1.09 1.12 1.08 1.06 1.05
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 282.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% -182.94% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
45.71 42.40 45.00 27.34 40.67 2.41 0.35 0.70 2.18 4.20 5.89
Noncontrolling Interest Sharing Ratio
0.00% 56.28% 0.00% 0.00% 0.00% 41.33% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
23.09 20.36 28.63 23.23 11.47 3.63 19.05 20.47 18.85 21.11 22.07
Quick Ratio
22.64 20.09 28.16 22.85 11.29 3.55 18.66 20.10 18.42 20.57 21.57
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-25 -21 -37 -31 16 10 27 24 -12 -24 -24
Operating Cash Flow to CapEx
-14,590.00% -6,092.62% -5,688.71% -11,875.94% 0.00% 0.00% 0.00% -56,350.00% -213,300.00% -2,196.77% -2,428.09%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.08 -5.06 -1.94 -3.31 -15 -15 -30 -24 12 13 11
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
13 10 28 21 -27 -28 -41 -34 2.94 5.67 6.19
Enterprise Value (EV)
514 585 436 245 1,082 230 -90 -96 -122 -90 -121
Market Capitalization
708 794 653 441 1,295 152 144 151 143 193 185
Book Value per Share
$6.97 $7.42 $7.83 $7.56 $42.01 ($1.60) $3.52 $3.86 $4.75 $5.10 $5.44
Tangible Book Value per Share
$6.97 $7.42 $7.83 $7.56 $42.01 ($1.60) $3.52 $3.86 $4.75 $5.10 $5.44
Total Capital
192 204 215 193 198 51 204 224 276 296 316
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-194 -209 -217 -196 -213 -66 -234 -247 -264 -284 -305
Capital Expenditures (CapEx)
0.11 0.15 0.19 0.13 0.00 0.00 0.00 0.02 0.01 1.02 0.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.80 -7.63 -4.23 -5.46 -16 -17 -7.74 -7.76 -8.13 -5.91 -6.72
Debt-free Net Working Capital (DFNWC)
189 202 213 191 198 49 226 239 256 262 285
Net Working Capital (NWC)
189 202 213 191 198 49 226 239 256 262 285
Net Nonoperating Expense (NNE)
2.77 1.99 1.15 0.21 5.39 6.20 4.97 4.25 3.84 5.87 6.37
Net Nonoperating Obligations (NNO)
-194 -209 -217 -196 -213 -66 -234 -248 -264 -284 -305
Total Depreciation and Amortization (D&A)
-1.10 -1.40 -1.35 -0.94 -0.27 -0.51 -0.52 -0.02 0.00 -0.44 0.09
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.53) $1.97 ($0.38) ($0.40) ($3.53) ($12.06) ($0.39) ($0.97) ($0.43) ($0.43) ($0.45)
Adjusted Weighted Average Basic Shares Outstanding
27.53M 21.28M 27.17M 25.61M 4.72M 1.96M 57.26M 56.75M 55.86M 54.87M 55.21M
Adjusted Diluted Earnings per Share
($0.53) $1.97 ($0.38) ($0.40) ($3.53) ($12.06) ($0.39) ($0.97) ($0.43) ($0.43) ($0.45)
Adjusted Weighted Average Diluted Shares Outstanding
27.53M 21.28M 27.17M 25.61M 4.72M 1.96M 57.26M 56.75M 55.86M 54.87M 55.21M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
28.15M 27.54M 27.50M 27.50M 25.53M 58.24M 58.00M 57.98M 58.10M 58.16M 58.15M
Normalized Net Operating Profit after Tax (NOPAT)
-12 -11 -9.06 -10 -11 -17 -14 -10 -8.83 -19 -18
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.44% 0.00% 0.00% -3.54% 0.00% 0.00% 0.00% -0.08% 0.00%

Frequently Asked Questions About LENZ Therapeutics' Financials

When does LENZ Therapeutics's financial year end?

According to the most recent income statement we have on file, LENZ Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has LENZ Therapeutics' net income changed over the last 2 years?

LENZ Therapeutics' net income appears to be on a downward trend, with a most recent value of -$49.77 million in 2024, falling from -$101.05 million in 2022. The previous period was -$69.97 million in 2023. See where experts think LENZ Therapeutics is headed by visiting LENZ Therapeutics' forecast page.

What is LENZ Therapeutics's operating income?
LENZ Therapeutics's total operating income in 2024 was -$58.61 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.61 million
How has LENZ Therapeutics revenue changed over the last 2 years?

Over the last 2 years, LENZ Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does LENZ Therapeutics have?

LENZ Therapeutics' total liabilities were at $11.22 million at the end of 2024, a 43.0% decrease from 2023, and a 56.2% decrease since 2022.

How much cash does LENZ Therapeutics have?

In the past 2 years, LENZ Therapeutics' cash and equivalents has ranged from $20.16 million in 2024 to $47.73 million in 2022, and is currently $20.16 million as of their latest financial filing in 2024.

How has LENZ Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, LENZ Therapeutics' book value per share changed from 5.10 in 2022 to 7.42 in 2024, a change of 45.6%.



This page (NASDAQ:LENZ) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners